Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...

DFA US Vector Equity Fund earns a High Process Pillar rating. The leading factor in the rating is its parent firm's impressive long-term risk-adjusted performance, as shown by the firm's average ...